Current Edition

Amgen

Novartis, Amgen settle their dueling lawsuits over migraine drug Aimovig

Novartis and Amgen have spent years arm wrestling one another over their development and commercialization deal on migraine prevention drug Aimovig. Now, the parties appear …

Continue Reading →
Amgen

For pharmas dealing with HCPs, the future is digital first—and sales reps 2nd

While many people are suffering from Zoom fatigue and looking forward to in-person meetups, that isn’t really the case when it comes to HCPs and …

Continue Reading →
Amgen

Amgen asks Supreme Court to take up its high-profile PCSK9 patent case against Sanofi and Regeneron

After Amgen earlier this year suffered a third consecutive loss in its high-profile PCSK9 patent feud with Sanofi and Regeneron, the company faced two choices: …

Continue Reading →
AbbVie

Biohaven taps Pfizer for global Nurtec push in deal worth up to $1.24B

Since scoring an FDA approval earlier this year to both treat and prevent migraine, Biohaven’s Nurtec ODT has jumped out ahead of Big Pharma rival …

Continue Reading →
Amgen

Amgen’s Repatha gains an edge on rival Praluent with FDA approval to treat children with rare cholesterol condition

Though it has struggled to live up to early commercial expectations, Amgen’s cholesterol treatment Repatha has largely had the best of its rival in the …

Continue Reading →
Amgen

Amgen scores Otezla patent win, protecting its blockbuster from Sandoz and Zydus generics until 2028

When Amgen bought marketing rights to psoriasis pill Otezla for $13.4 billion two years ago, the company was likely counting on not having to compete …

Continue Reading →